MRI-guided Radiotherapy (MRgRT) for Treatment of Oligometastases: Review of Clinical Applications and Challenges

Hellman, 1995, Oligometastases, J Clin Oncol, 13, 8, 10.1200/JCO.1995.13.1.8 Reyes, 2015, The biology and treatment of oligometastatic cancer, Oncotarget, 6, 8491, 10.18632/oncotarget.3455 Alshehri, 2020, Highlights on the management of oligometastatic disease, J Immunother Precision Oncol, 3, 34, 10.4103/JIPO.JIPO_24_19 Fleckenstein, 2016, Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer, BMC Cancer, 16, 348, 10.1186/s12885-016-2379-x Niibe, 2010, Oligometastases and oligo-recurrence: The new era of cancer therapy, Jpn J Clin Oncol, 40, 107, 10.1093/jjco/hyp167 Timmerman, 2010, Stereotactic body radiation therapy for inoperable early stage lung cancer, JAMA, 303, 1070, 10.1001/jama.2010.261 Brown, 2013, Dose escalation, not “new biology,” can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer, Int J Radiat Oncol Biol Phys, 85, 1159, 10.1016/j.ijrobp.2012.11.003 Chmura, 2021, Evaluation of safety of stereotactic body radiotherapy for the treatment of patients with multiple metastases: Findings from the NRG-BR001 phase 1 trial, JAMA Oncol, 7, 845, 10.1001/jamaoncol.2021.0687 deSouza, 2018, Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer Imaging Group, Eur J Cancer, 91, 153, 10.1016/j.ejca.2017.12.012 Milano, 2019, Signals from SABR-COMET time to move on to phase III studies, Ann Transl Med, 7, S316, 10.21037/atm.2019.09.152 Milano, 2012, Oligometastases treated with stereotactic body radiotherapy: Long-term follow-up of prospective study, Int J Radiat Oncol Biol Phys, 83, 878, 10.1016/j.ijrobp.2011.08.036 Palma, 2019, Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial, Lancet, 393, 2051, 10.1016/S0140-6736(18)32487-5 Palma, 2020, Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET phase II randomized trial, J Clin Oncol, 38, 2830, 10.1200/JCO.20.00818 Pitroda, 2019, Integration of radiotherapy and immunotherapy for treatment of oligometastases, Lancet Oncol, 20, e434, 10.1016/S1470-2045(19)30157-3 Sahgal, 2012, The Canadian Association of Radiation Oncology scope of practice guidelines for lung, liver and spine stereotactic body radiotherapy, Clin Oncol (R Coll Radiol), 24, 629, 10.1016/j.clon.2012.04.006 Tree, 2013, Stereotactic body radiotherapy for oligometastases, Lancet Oncol, 14, e28, 10.1016/S1470-2045(12)70510-7 Salama, 2012, Stereotactic body radiotherapy for multisite extracranial oligometastases: Final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease, Cancer, 118, 2962, 10.1002/cncr.26611 Onderdonk, 2020, The evolution (and future) of stereotactic body radiotherapy in the treatment of oligometastatic disease, Hematol Oncol Clin North Am, 34, 307, 10.1016/j.hoc.2019.09.003 Luke, 2020, Improved survival associated with local tumor response following multisite radiotherapy and pembrolizumab: Secondary analysis of a phase I trial, Clin Cancer Res, 26, 6437, 10.1158/1078-0432.CCR-20-1790 Okunieff, 2018, Report from the SWOG radiation oncology committee: Research objectives workshop 2017, Clin Cancer Res, 24, 3500, 10.1158/1078-0432.CCR-17-3202 Chaung, 2021, Limited brain metastases: A narrative review, Ann Palliat Med, 10, 6016, 10.21037/apm-21-363 Maclean, 2013, Multi-disciplinary management for patients with oligometastases to the brain: Results of a 5 year cohort study, Radiat Oncol, 8, 156, 10.1186/1748-717X-8-156 Villarreal-Garza, 2013, Aggressive treatment of primary tumor in patients with non-small-cell lung cancer and exclusively brain metastases, Clin Lung Cancer, 14, 6, 10.1016/j.cllc.2012.05.002 Bergsma, 2017, Radiotherapy for oligometastatic lung cancer, Front Oncol, 7, 210, 10.3389/fonc.2017.00210 Bezjak, 2019, Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG oncology/RTOG 0813 trial, J Clin Oncol, 37, 1316, 10.1200/JCO.18.00622 Eichhorn, 2021, How to handle oligometastatic disease in nonsmall cell lung cancer, Eur Resp Rev, 30 Finazzi, 2020, Clinical outcomes of stereotactic MR-guided adaptive radiation therapy for high-risk lung tumors, Int J Radiat Oncol Biol Phys, 107, 270, 10.1016/j.ijrobp.2020.02.025 Gomez, 2016, Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: A multicentre, randomised, controlled, phase 2 study, Lancet Oncol, 17, 1672, 10.1016/S1470-2045(16)30532-0 Gomez, 2019, Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: Long-term results of a multi-institutional, phase II, randomized study, J Clin Oncol, 37, 1558, 10.1200/JCO.19.00201 Iyengar, 2018, Consolidative radiotherapy for limited metastatic non–small-cell lung cancer: A phase 2 randomized clinical trial, JAMA Oncol, 4, 10.1001/jamaoncol.2017.3501 Kim, 2017, Role of local ablative therapy in patients with oligometastatic and oligoprogressive non-small cell lung cancer, J Thorac Oncol, 12, 179, 10.1016/j.jtho.2016.10.012 Mehta, 2004, Analysis of further disease progression in metastatic non-small cell lung cancer: Implications for locoregional treatment, Int J Oncol, 25, 1677 Rusthoven, 2009, Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases, J Clin Oncol, 27, 1579, 10.1200/JCO.2008.19.6386 Stephens, 2018, Managing patients with oligometastatic non–small-cell lung cancer, J Oncol Pract, 14, 23, 10.1200/JOP.2017.026500 Siva, 2017, Stereotactic ablative body radiotherapy for lung metastases: Where is the evidence and what are we doing with it?, Semin Radiat Oncol, 27, 229, 10.1016/j.semradonc.2017.03.003 Romesser, 2021, Magnetic resonance imaging-guided adaptive radiotherapy for colorectal liver metastases, Cancers, 13, 1636, 10.3390/cancers13071636 Rosenberg, 2019, A multi-institutional experience of MR-guided liver stereotactic body radiation therapy, Adv Radiat Oncol, 4, 142, 10.1016/j.adro.2018.08.005 Rusthoven, 2009, Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases, J Clin Oncol, 27, 1572, 10.1200/JCO.2008.19.6329 Bruynzeel, 2019, A prospective single-arm phase 2 study of stereotactic magnetic resonance guided adaptive radiation therapy for prostate cancer: Early toxicity results, Int J Radiat Oncol Biol Phys, 105, 1086, 10.1016/j.ijrobp.2019.08.007 Ost, 2018, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II trial, J Clin Oncol, 36, 446, 10.1200/JCO.2017.75.4853 Palacios-Eito, 2019, Oligometastases in prostate cancer: Ablative treatment, World J Clin Oncol, 10, 38, 10.5306/wjco.v10.i2.38 Phillips, 2020, Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial, JAMA Oncol, 6, 650, 10.1001/jamaoncol.2020.0147 Borghesi, 2022, Stereotactic body radiation therapy for adrenal oligometastases, Rep Pract Oncol Radiother, 27, 52, 10.5603/RPOR.a2021.0104 De Ruysscher, 2018, Progression-free survival and overall survival beyond 5 years of NSCLC patients with synchronous oligometastases treated in a prospective phase II trial (NCT 01282450), J Thorac Oncol, 13, 1958, 10.1016/j.jtho.2018.07.098 Matsushita, 2018, Stereotactic radiotherapy for oligometastases in lymph nodes-a review, Technol Cancer Res Treat, 17, 10.1177/1533033818803597 Chmura, 2019, NRG-BR002: A phase IIr/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer (NCT02364557), J Clin Oncol, 37, 10.1200/JCO.2019.37.15_suppl.TPS1117 Andratschke, 2015, Stereotactic radiation therapy for liver metastases: Factors affecting local control and survival, Radiat Oncol, 10, 69, 10.1186/s13014-015-0369-9 Comito, 2015, Liver metastases and SBRT: A new paradigm?, Rep Pract Oncol Radiother, 20, 464, 10.1016/j.rpor.2014.10.002 Dawson, 2019, NRG oncology/RTOG 0438: A phase 1 trial of highly conformal radiation therapy for liver metastases, Pract Radiat Oncol, 9, e386, 10.1016/j.prro.2019.02.013 Hong, 2016, Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma, J Clin Oncol, 34, 460, 10.1200/JCO.2015.64.2710 Nair, 2014, Treatment of metastatic liver tumors using stereotactic ablative radiotherapy, World J Radiol, 6, 18, 10.4329/wjr.v6.i2.18 Johnson, 2022, Proton radiotherapy for patients with oligometastatic breast cancer involving the sternum, Int J Part Ther, 8, 66, 10.14338/IJPT-21-00014 Sulaiman, 2014, Particle beam radiation therapy using carbon ions and protons for oligometastatic lung tumors, Radiat Oncol, 9, 183, 10.1186/1748-717X-9-183 Demizu, 2014, Carbon ion therapy for early-stage non-small-cell lung cancer, BioMed Res Int, 2014, 10.1155/2014/727962 Milano, 2022, Cautioning against declaring success before the finish line, Int J Radiat Oncol Biol Phys, 112, 376, 10.1016/j.ijrobp.2021.10.007 Fallone, 2014, The rotating biplanar linac-magnetic resonance imaging system, Semin Radiat Oncol, 24, 200, 10.1016/j.semradonc.2014.02.011 Keall, 2014, The australian magnetic resonance imaging-linac program, Semin Radiat Oncol, 24, 203, 10.1016/j.semradonc.2014.02.015 Kupelian, 2014, Magnetic resonance-guided adaptive radiotherapy: A solution to the future, Semin Radiat Oncol, 24, 227, 10.1016/j.semradonc.2014.02.013 Lagendijk, 2014, The magnetic resonance imaging-linac system, Semin Radiat Oncol, 24, 207, 10.1016/j.semradonc.2014.02.009 Mutic, 2014, The ViewRay system: Magnetic resonance-guided and controlled radiotherapy, Semin Radiat Oncol, 24, 196, 10.1016/j.semradonc.2014.02.008 Devic, 2012, MRI simulation for radiotherapy treatment planning, Med Phys, 39, 6701, 10.1118/1.4758068 Chin, 2020, Magnetic resonance-guided radiation therapy: A review, J Med Imaging Radiat Oncol, 64, 163, 10.1111/1754-9485.12968 Derynda, 2021, MR-guided radiation therapy for oligometastatic malignancies, Appl Rad Oncol, 10, 25, 10.37549/ARO1282 Acharya, 2016, Magnetic resonance image guided radiation therapy for external beam accelerated partial-breast irradiation: Evaluation of delivered dose and intrafractional cavity motion, Int J Radiat Oncol Biol Phys, 96, 785, 10.1016/j.ijrobp.2016.08.006 Alam, 2022, Inter- and intrafraction motion assessment and accumulated dose quantification of upper gastrointestinal organs during magnetic resonance-guided ablative radiation therapy of pancreas patients, Phys Imaging Radiat Oncol, 21, 54, 10.1016/j.phro.2022.02.007 de Muinck Keizer, 2020, Prostate intrafraction motion during the preparation and delivery of MR-guided radiotherapy sessions on a 1.5t MR-LINAC, Radiother Oncol, 151, 88, 10.1016/j.radonc.2020.06.044 den Boer, 2021, Comparison of library of plans with two daily adaptive strategies for whole bladder radiotherapy, Phys Imaging Radiat Oncol, 20, 82, 10.1016/j.phro.2021.11.002 Hegde, 2018, Magnetic resonance imaging guidance mitigates the effects of intrafraction prostate motion during stereotactic body radiotherapy for prostate cancer, Cureus, 10, e2442 Prins, 2019, Intrafraction motion management of renal cell carcinoma with magnetic resonance imaging-guided stereotactic body radiation therapy, Pract Radiat Oncol, 9, e55, 10.1016/j.prro.2018.09.002 Bainbridge, 2017, Magnetic resonance imaging in precision radiation therapy for lung cancer, Transl Lung Cancer Res, 6, 689, 10.21037/tlcr.2017.09.02 Corradini, 2019, MR-guidance in clinical reality: Current treatment challenges and future perspectives, Radiat Oncol, 14, 92, 10.1186/s13014-019-1308-y Finazzi, 2019, Role of on-table plan adaptation in MR-guided ablative radiation therapy for central lung tumors, Int J Radiat Oncol Biol Phys, 104, 933, 10.1016/j.ijrobp.2019.03.035 Lim-Reinders, 2017, Online adaptive radiation therapy, Int J Radiat Oncol Biol Phys, 99, 994, 10.1016/j.ijrobp.2017.04.023 Winkel, 2019, Adaptive radiotherapy: The Elekta unity MR-LINAC concept, Clin Transl Radiat Oncol, 18, 54, 10.1016/j.ctro.2019.04.001 Yan, 1997, Adaptive radiation therapy, Phys Med Biol, 42, 123, 10.1088/0031-9155/42/1/008 Boldrini, 2018, Use of indirect target gating in magnetic resonance-guided liver stereotactic body radiotherapy: Case report of an oligometastatic patient, Cureus, 10, e2292 Fast, 2019, Tumor trailing for liver sbrt on the MR-LINAC, Int J Radiat Oncol Biol Phys, 103, 468, 10.1016/j.ijrobp.2018.09.011 Feldman, 2019, Real-time magnetic resonance-guided liver stereotactic body radiation therapy: An institutional report using a magnetic resonance-linac system, Cureus, 11 Hal, 2020, Initial clinical experience of stereotactic body radiation therapy (SBRT) for liver metastases, primary liver malignancy, and pancreatic cancer with 4D-MRI based online adaptation and real-time MRI monitoring using a 1.5 tesla MR-LINAC, PLoS One, 15, 10.1371/journal.pone.0236570 Henke, 2018, Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen, Radiother Oncol, 126, 519, 10.1016/j.radonc.2017.11.032 Henke, 2016, Simulated online adaptive magnetic resonance-guided stereotactic body radiation therapy for the treatment of oligometastatic disease of the abdomen and central thorax: Characterization of potential advantages, Int J Radiat Oncol Biol Phys, 96, 1078, 10.1016/j.ijrobp.2016.08.036 Ugurluer, 2021, Stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of liver metastases in oligometastatic patients: Initial clinical experience, Radiat Oncol J, 39, 33, 10.3857/roj.2020.00976 van Dams, 2021, Role of MR-guided radiotherapy (MRgRT) in colorectal cancer, Curr Colorectal Cancer Rep, 17, 69, 10.1007/s11888-021-00467-6 Bruynzeel, 2019, The role of biological dose-escalation for pancreatic cancer, Clin Transl Radiat Oncol, 18, 128, 10.1016/j.ctro.2019.04.020 Sperti, 2014, Metastatic tumors to the pancreas: The role of surgery, World J Gastrointest Oncol, 6, 381, 10.4251/wjgo.v6.i10.381 Boldrini, 2019, Online adaptive magnetic resonance guided radiotherapy for pancreatic cancer: State of the art, pearls and pitfalls, Radiat Oncol, 14, 71, 10.1186/s13014-019-1275-3 Chuong, 2021, Ablative 5-fraction stereotactic magnetic resonance-guided radiation therapy with on-table adaptive replanning and elective nodal irradiation for inoperable pancreas cancer, Pract Radiat Oncol, 11, 134, 10.1016/j.prro.2020.09.005 Hassanzadeh, 2020, Ablative five-fraction stereotactic body radiation therapy for inoperable pancreatic cancer using online mr-guided adaptation, Adv Radiat Oncol, 6 Heerkens, 2018, MRI guided stereotactic radiotherapy for locally advanced pancreatic cancer, Br J Radiol, 91, 10.1259/bjr.20170563 Rudra, 2019, Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer, Cancer Med, 8, 2123, 10.1002/cam4.2100 Tyagi, 2021, Feasibility of ablative stereotactic body radiation therapy of pancreas cancer patients on a 1.5 tesla magnetic resonance-linac system using abdominal compression, Phys Imaging Radiat Oncol, 19, 53, 10.1016/j.phro.2021.07.006 Chuong, 2020, Case report of ablative magnetic resonance-guided stereotactic body radiation therapy for oligometastatic mesenteric lymph nodes from bladder cancer, Ther Radiol Oncol, 4, 10.21037/tro-20-37 Cuccia, 2021, Mitigation on bowel loops daily variations by 1.5-t MR-guided daily-adaptive SBRT for abdomino-pelvic lymph-nodal oligometastases, J Cancer Res Clin Oncol, 147, 3269, 10.1007/s00432-021-03739-8 Winkel, 2020, Target coverage and dose criteria based evaluation of the first clinical 1.5t MR-LINAC SBRT treatments of lymph node oligometastases compared with conventional CBCT-LINAC treatment, Radiother Oncol, 146, 118, 10.1016/j.radonc.2020.02.011 Winkel, 2018, Simulated dosimetric impact of online replanning for stereotactic body radiation therapy of lymph node oligometastases on the 1.5t MR-LINAC, Acta Oncol, 57, 1705, 10.1080/0284186X.2018.1512152 Winkel, 2021, Dosimetric feasibility of hypofractionation for SBRT treatment of lymph node oligometastases on the 1.5t MR-LINAC, Radiother Oncol, 154, 243, 10.1016/j.radonc.2020.09.020 Zhang, 2019, Stereotactic ablative radiation therapy (SABR) used to defer systemic therapy in oligometastatic renal cell cancer, Int J Radiat Oncol Biol Phys, 105, 367, 10.1016/j.ijrobp.2019.07.023 Keller, 2021, Adaptive magnetic resonance-guided stereotactic body radiotherapy: The next step in the treatment of renal cell carcinoma, Front Oncol, 11, 10.3389/fonc.2021.634830 Kerkhof, 2011, A new concept for non-invasive renal tumour ablation using real-time MRI-guided radiation therapy, BJU Int, 107, 63, 10.1111/j.1464-410X.2010.09458.x Rudra, 2019, Magnetic resonance image guided stereotactic body radiation therapy to the primary renal mass in metastatic renal cell carcinoma, Adv Radiat Oncol, 4, 566, 10.1016/j.adro.2019.04.002 Tetar, 2020, The role of daily adaptive stereotactic MR-guided radiotherapy for renal cell cancer, Cancers (Basel), 12, 2763, 10.3390/cancers12102763 Timmerman, 2006, Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer, J Clin Oncol, 24, 4833, 10.1200/JCO.2006.07.5937 Lindberg, 2021, The HILUS-trial-a prospective nordic multicenter phase 2 study of ultracentral lung tumors treated with stereotactic body radiotherapy, J Thorac Oncol, 16, 1200, 10.1016/j.jtho.2021.03.019 Crockett, 2021, Initial clinical experience of MR-guided radiotherapy for non-small cell lung cancer, Front Oncol, 11, 10.3389/fonc.2021.617681 Henke, 2019, Stereotactic MR-guided online adaptive radiation therapy (SMART) for ultracentral thorax malignancies: Results of a phase 1 trial, Adv Radiat Oncol, 4, 201, 10.1016/j.adro.2018.10.003 Thomas, 2018, Initial clinical observations of intra- and interfractional motion variation in MR-guided lung SBRT, Br J Radiol, 91 Weng, 2021, High-field MR-guided radiation therapy for oligometastatic central lung cancer: Current state and future opportunities, Appl Rad Oncol, 10, 40, 10.37549/ARO1299 Draulans, 2020, Primary endpoint analysis of the multicentre phase II HYPO-FLAME trial for intermediate and high risk prostate cancer, Radiother Oncol, 147, 92, 10.1016/j.radonc.2020.03.015 Muldermans, 2016, Stereotactic body radiation therapy for oligometastatic prostate cancer, Int J Radiat Oncol Biol Phys, 95, 696, 10.1016/j.ijrobp.2016.01.032 Niazi, 2018, Local ablative stereotactic body radiotherapy for oligometastatic prostate cancer, Curr Opin Support Palliat Care, 12, 351, 10.1097/SPC.0000000000000371 Widmark, 2019, Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial, Lancet, 394, 385, 10.1016/S0140-6736(19)31131-6 Siva, 2018, Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: A prospective clinical trial, Eur Urol, 74, 455, 10.1016/j.eururo.2018.06.004 Alongi, 2020, 1.5 t MR-guided and daily adapted SBRT for prostate cancer: Feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment, Radiat Oncol, 15, 69, 10.1186/s13014-020-01510-w Mohajer, 2021, Feasibility of MR-guided ultrahypofractionated radiotherapy in 5, 2 or 1 fractions for prostate cancer, Clin Transl Radiat Oncol, 26, 1, 10.1016/j.ctro.2020.10.005 Sandoval, 2021, Non-adaptive MR-guided radiotherapy for prostate sbrt: Less time, equal results, J Clin Med, 10, 3396, 10.3390/jcm10153396 Tetar, 2021, Magnetic resonance-guided stereotactic radiotherapy for localized prostate cancer: Final results on patient-reported outcomes of a prospective phase 2 study, Eur Urol Oncol, 4, 628, 10.1016/j.euo.2020.05.007 Fokdal, 2016, Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroembrace study, Radiother Oncol, 120, 434, 10.1016/j.radonc.2016.03.020 Cree, 2018, The potential value of MRI in external-beam radiotherapy for cervical cancer, Clin Oncol (R Coll Radiol), 30, 737, 10.1016/j.clon.2018.08.002 Henke, 2022, Phase I trial of stereotactic MRI-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic ovarian cancer, Int J Radiat Oncol Biol Phys, 112, 379, 10.1016/j.ijrobp.2021.08.033 Makhlin, 2020, Oligometastatic breast cancer: Is this a curable entity? A contemporary review of the literature, Curr Oncol Rep, 22, 10.1007/s11912-020-0867-2 Price, 2021, Implementing stereotactic accelerated partial breast irradiation using magnetic resonance guided radiation therapy, Radiother Oncol, 164, 275, 10.1016/j.radonc.2021.09.023 Groot Koerkamp, 2020, Optimizing MR-guided radiotherapy for breast cancer patients, Front Oncol, 10, 10.3389/fonc.2020.01107 Tyran, 2018, Stereotactic magnetic resonance-guided online adaptive radiotherapy for oligometastatic breast cancer: A case report, Cureus, 10, e2368 Simonetto, 2019, Does deep inspiration breath-hold prolong life? Individual risk estimates of ischaemic heart disease after breast cancer radiotherapy, Radiother Oncol, 131, 202, 10.1016/j.radonc.2018.07.024 Ippolito, 2015, SBRT: A viable option for treating adrenal gland metastases, Rep Pract Oncol Radiother, 20, 484, 10.1016/j.rpor.2015.05.009 Scorsetti, 2012, Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: A retrospective analysis of 34 patients, Acta Oncol, 51, 618, 10.3109/0284186X.2011.652738 Palacios, 2018, Role of daily plan adaptation in MR-guided stereotactic ablative radiation therapy for adrenal metastases, Int J Radiat Oncol Biol Phys, 102, 426, 10.1016/j.ijrobp.2018.06.002 Cao, 2017, MR-guided radiation therapy: Transformative technology and its role in the central nervous system, Neuro Oncol, 19, ii16, 10.1093/neuonc/nox006 Tseng, 2017, Dosimetric feasibility of the hybrid magnetic resonance imaging (MRI)-LINAC system (MRL) for brain metastases: The impact of the magnetic field, Radiother Oncol, 125, 273, 10.1016/j.radonc.2017.09.036 Wen, 2018, Evaluation of a magnetic resonance guided linear accelerator for stereotactic radiosurgery treatment, Radiother Oncol, 127, 460, 10.1016/j.radonc.2018.04.034 Maziero, 2021, MR-guided radiotherapy for brain and spine tumors, Front Oncol, 11, 600, 10.3389/fonc.2021.626100 Mehta, 2018, Daily tracking of glioblastoma resection cavity, cerebral edema, and tumor volume with mri-guided radiation therapy, Cureus, 10, e2346 Tan, 2022, Inter-fraction dynamics during post-operative 5 fraction cavity hypofractionated stereotactic radiotherapy with a MR LINAC: A prospective serial imaging study, J Neurooncol, 156, 569, 10.1007/s11060-021-03938-w Raaymakers, 2017, First patients treated with a 1.5 t MRI-LINAC: Clinical proof of concept of a high-precision, high-field mri guided radiotherapy treatment, Phys Med Biol, 62, L41, 10.1088/1361-6560/aa9517 Spieler, 2020, Advantages of radiation therapy simulation with 0.35 tesla magnetic resonance imaging for stereotactic ablation of spinal metastases, Pract Radiat Oncol, 10, 339, 10.1016/j.prro.2019.10.018 Henke, 2019, First reported case of pediatric radiation treatment with magnetic resonance image guided radiation therapy, Adv Radiat Oncol, 4, 233, 10.1016/j.adro.2019.01.008 Egriboyun, 2021, Magnetic resonance image-guided stereotactic body radiation therapy for liver rhabdoid tumor in infancy: A case report, J Med Imaging Radiat Sci, 52, 305, 10.1016/j.jmir.2021.02.006 Seravalli, 2021, The potential role of MR-guided adaptive radiotherapy in pediatric oncology: Results from a SIOPE-COG survey, Clin Transl Radiat Oncol, 29, 71, 10.1016/j.ctro.2021.05.008 Kurz, 2020, Medical physics challenges in clinical MR-guided radiotherapy, Radiat Oncol, 15, 93, 10.1186/s13014-020-01524-4 McWilliam, 2018, The challenges of using MRI during radiotherapy, Clin Oncol (R Coll Radiol), 30, 680, 10.1016/j.clon.2018.08.004 Thorwarth, 2021, Technical challenges of real-time adaptive MR-guided radiotherapy, Front Oncol, 11, 10.3389/fonc.2021.634507 van Herk, 2018, Magnetic resonance imaging-guided radiation therapy: A short strengths, weaknesses, opportunities, and threats analysis, Int J Radiat Oncol Biol Phys, 101, 1057, 10.1016/j.ijrobp.2017.11.009 Nejad-Davarani, 2019, Large field of view distortion assessment in a low-field MR-LINAC, Med Phys, 46, 2347, 10.1002/mp.13467 Glide-Hurst, 2018, Per-organ assessment of subject-induced susceptibility distortion for MR-only male pelvis treatment planning, Radiat Oncol, 13, 149, 10.1186/s13014-018-1090-2 Stanescu, 2012, Characterization of tissue magnetic susceptibility-induced distortions for mrigrt, Med Phys, 39, 7185, 10.1118/1.4764481 Hackett, 2018, Spiraling contaminant electrons increase doses to surfaces outside the photon beam of an MRI-LINAC with a perpendicular magnetic field, Phys Med Biol, 63, 10.1088/1361-6560/aaba8f Raaymakers, 2004, Integrating a MRI scanner with a 6 mv radiotherapy accelerator: Dose deposition in a transverse magnetic field, Phys Med Biol, 49, 4109, 10.1088/0031-9155/49/17/019 Kirkby, 2010, Lung dosimetry in a LINAC-MRI radiotherapy unit with a longitudinal magnetic field, Med Phys, 37, 4722, 10.1118/1.3475942 Raaijmakers, 2007, Dose optimization for the MRI-accelerator: IMRT in the presence of a magnetic field, Phys Med Biol, 52, 7045, 10.1088/0031-9155/52/23/018 Bol, 2015, Compensating for the impact of non-stationary spherical air cavities on IMRT dose delivery in transverse magnetic fields, Phys Med Biol, 60, 755, 10.1088/0031-9155/60/2/755 Han, 2018, Respiratory motion-resolved, self-gated 4D-MRI using rotating cartesian k-space (ROCK): Initial clinical experience on an MRI-guided radiotherapy system, Radiother Oncol, 127, 467, 10.1016/j.radonc.2018.04.029 Terpstra, 2020, Deep learning-based image reconstruction and motion estimation from undersampled radial k-space for real-time MRI-guided radiotherapy, Phys Med Biol, 65, 10.1088/1361-6560/ab9358 Borman, 2018, Characterization of imaging latency for real-time MRI-guided radiotherapy, Phys Med Biol, 63, 10.1088/1361-6560/aad2b7 Green, 2018, First clinical implementation of real-time, real anatomy tracking and radiation beam control, Med Phys, 45, 3728, 10.1002/mp.13002 Güngör, 2021, Time analysis of online adaptive magnetic resonance-guided radiation therapy workflow according to anatomical sites, Pract Radiat Oncol, 11, e11, 10.1016/j.prro.2020.07.003 Tetar, 2019, Clinical implementation of magnetic resonance imaging guided adaptive radiotherapy for localized prostate cancer, Phys Imaging Radiat Oncol, 9, 69, 10.1016/j.phro.2019.02.002 Bohoudi, 2017, Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer, Radiother Oncol, 125, 439, 10.1016/j.radonc.2017.07.028 Chetty, 2017, Adaptive radiation therapy: Off-line, on-line, and in-line?, Int J Radiat Oncol Biol Phys, 99, 689, 10.1016/j.ijrobp.2017.07.017 Zhong, 2017, Caution must be exercised when performing deformable dose accumulation for tumors undergoing mass changes during fractionated radiation therapy, Int J Radiat Oncol Biol Phys, 97, 182, 10.1016/j.ijrobp.2016.09.012 van Herk, 2000, The probability of correct target dosage: Dose-population histograms for deriving treatment margins in radiotherapy, Int J Radiat Oncol Biol Phys, 47, 1121, 10.1016/S0360-3016(00)00518-6 Engels, 2014, Impact of planning target volume margins and rectal distention on biochemical failure in image-guided radiotherapy of prostate cancer, Radiother Oncol, 111, 106, 10.1016/j.radonc.2014.02.009 Billas, 2021, Traceable reference dosimetry in MRI guided radiotherapy using alanine: Calibration and magnetic field correction factors of ionisation chambers, Phys Med Biol, 66 Pojtinger, 2018, Ionization chamber correction factors for MR-LINACS, Phys Med Biol, 63, 11nt03, 10.1088/1361-6560/aac4f2 Cervantes, 2021, Monte Carlo calculation of detector perturbation and quality correction factors in a 1.5 t magnetic resonance guided radiation therapy small photon beams, Phys Med Biol, 66 O'Brien, 2016, Reference dosimetry in magnetic fields: Formalism and ionization chamber correction factors, Med Phys, 43, 4915, 10.1118/1.4959785 Reynolds, 2017, Technical note: Ion chamber angular dependence in a magnetic field, Med Phys, 44, 4322, 10.1002/mp.12405 Reynoso, 2016, Technical note: Magnetic field effects on gafchromic-film response in MR-IGRT, Med Phys, 43, 6552, 10.1118/1.4967486 Steinmann, 2019, Investigation of TLD and EBT3 performance under the presence of 1.5t, 0.35t, and 0t magnetic field strengths in MR/CT visible materials, Med Phys, 46, 3217, 10.1002/mp.13527 Torres-Xirau, 2018, Characterization of the A-SI EPID in the unity MR-LINAC for dosimetric applications, Phys Med Biol, 63, 10.1088/1361-6560/aa9dbf Levine, 2007, Safety of magnetic resonance imaging in patients with cardiovascular devices, Circulation, 116, 2878, 10.1161/CIRCULATIONAHA.107.187256 de Mol van Otterloo, 2021, Patterns of care, tolerability, and safety of the first cohort of patients treated on a novel high-field MR-LINAC within the momentum study: Initial results from a prospective multi-institutional registry, Int J Radiat Oncol Biol Phys, 111, 867, 10.1016/j.ijrobp.2021.07.003 Chang, 2022, How vital are patient-reported outcomes?, J Natl Cancer Inst, 114, 347, 10.1093/jnci/djab178 Siddiqui, 2014, Patient-reported outcomes and survivorship in radiation oncology: Overcoming the cons, J Clin Oncol, 32, 2920, 10.1200/JCO.2014.55.0707 Rodgers, 2020, Comparison of radiographer interobserver image registration variability using cone beam CT and MR for cervix radiotherapy, Br J Radiol, 93, 10.1259/bjr.20200169 Mao, 2022, Evaluation of auto-contouring and dose distributions for online adaptive radiation therapy of patients with locally advanced lung cancers, Pract Radiat Oncol, 12, e329, 10.1016/j.prro.2021.12.017 Hales, 2020, Therapeutic radiographers at the helm: Moving towards radiographer-led MR-guided radiotherapy, J Med Imaging Radiat Sci, 51, 364, 10.1016/j.jmir.2020.05.001 Li, 2022, Synthetic computed tomography generation from 0.35t magnetic resonance images for magnetic resonance-only radiation therapy planning using perceptual loss models, Pract Radiat Oncol, 12, e40, 10.1016/j.prro.2021.08.007 Tyagi, 2017, Dosimetric and workflow evaluation of first commercial synthetic CT software for clinical use in pelvis, Phys Med Biol, 62, 2961, 10.1088/1361-6560/aa5452 Surucu, 2021, Comparison of a first-in-class LINAC-integrated pet system and a diagnostic PET/CT scanner, Int J Radiat Oncol Biol Phys, 111, e515, 10.1016/j.ijrobp.2021.07.1411 Hörner-Rieber, 2021, MR-guided radiotherapy: The perfect partner for immunotherapy?, Front Oncol, 10, 10.3389/fonc.2020.615697